PIpepTolDC tolerogenic dendritic-cell vaccine
City of Hope / investigator-led
A personalized immune-tolerance vaccine made from a person's own dendritic cells loaded with proinsulin peptide, being tested by City of Hope in a small phase 1 T1D safety/manufacturing study. The goal is to teach immune tolerance to beta-cell antigens, but efficacy is completely unproven.
The scorecard
The registered phase 1 study is focused on safety and manufacturing; no beta-cell-preservation efficacy result has been posted.[1]
Safety is exactly what the small phase 1 trial is assessing; until results post, risk is uncertain and manufacturing burden is high.[1]
Personalized cell manufacturing plus the current adult-only phase 1 design make broad eligibility speculative.[1]
Earliest human stage: Phase 1 enrollment complete (actual n=6); primary completion 3 June 2024; still active-not-recruiting for follow-up (estimated completion 15 December 2026). No results posted.[1]
The full picture
PIpepTolDC belongs on the horizon list, not the near-term treatment list. It is scientifically elegant — a patient-specific dendritic-cell product designed to teach tolerance to proinsulin — but still at phase 1 safety and feasibility.
The registered study (NCT04590872) has finished enrollment (actual n=6). Primary completion was 3 June 2024; the record remains active, not recruiting, with estimated study completion 15 December 2026 and last update 22 April 2026. No results are posted. A passed primary-completion date is not an efficacy readout.
Coming soon
ETA · Phase 1 enrollment complete (n=6 actual); primary completion 3 June 2024; follow-up estimated through 15 December 2026. No results posted.
- →Phase 1 safety and manufacturing results
Sources
- [1]An Immunotherapy Vaccine PIpepTolDC for the Treatment of Patients With Type 1 Diabetes · registry · 2026-04-22